Le Lézard
Classified in: Health
Subject: FDA

510(k) Market Clearance for FluChip-8G Influenza A+B Assay

BOULDER, Colo., April 30, 2019 /PRNewswire/ -- InDevR Inc., a leader in progressive analytical technologies, announced today that they have received 510(k) market clearance for their FluChip-8G Influenza A+B Assay from the United States Food and Drug Administration (FDA).

FluChip-8G is the first cleared influenza diagnostic capable of positively characterizing a wide variety of viruses as "non-seasonal" and characterizing seasonal viruses in a single multiplexed assay with same-day results.

According to Dr. Nancy Cox, retired former director of the Influenza Division within the Centers for Disease Control and Prevention,

"This is a tremendous accomplishment by the extraordinary team of scientists and engineers at InDevR. I applaud their efforts to develop an in vitro diagnostic that can be used as an early warning system for the emergence of new strains of influenza." 

The in vitro diagnostic assay was developed for the qualitative detection and differentiation of seasonal and non-seasonal influenza A viruses as well as the genetic lineage of influenza B viruses. Importantly, the assay is capable of detecting a wide variety of non-seasonal influenza A viruses and positively identifying them as "non-seasonal," including subtypes with recognized pandemic potential such as H7N9 and H5N1. The open platform molecular diagnostic system consists of a low-density microarray and reagent kit, microarray imaging system, and custom software. The assay is based on multiplexed RT-PCR amplification of whole influenza gene segments in combination with detection on a microarray and subsequent AI-based pattern-recognition for automated interpretation.

Dr. Erica Dawson, InDevR's Chief Technology Officer said:

"We are excited about InDevR's first 510(k) market clearance for the FluChip-8G Influenza A+B Assay. This successful clearance follows several years of assay development with the goal of improving the nation's preparedness to respond to an influenza pandemic. We hope that placement of this FluChip-8G technology in the field will bring us another step closer to ensuring timely detection of emerging influenza threats."

Early development of the FluChip-8G technology was supported by a Small Business Innovation Research Grant R43/44 AI077112 through the National Institutes for Allergy and Infectious Disease (NIAID); National Institutes of Health (NIH). Advanced development of the FluChip-8G platform has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201400010C and HHSO100201500024C.

The content of this news release is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or BARDA.

About InDevR

InDevR is a global leader in progressive new analytical technologies that enable accelerated development and manufacturing of vaccines and other biotherapeutics. Other InDevR products include the VaxArray portfolio of game-changing multiplexed potency assays for vaccines and the Cypher One system for digital imaging and automated interpretation of hemagglutination assays. For more information about the company and products, please visit www.indevr.com or call 303-402-9100.


Shannon Rodriguez


Related Images

FluChip-8G instrument

Related Links

InDevR Website Product Page


These press releases may also interest you

at 17:35
Technavio has been monitoring the oligonucleotide synthesis market and it is poised to grow by USD 1.02 bn during 2019-2023, progressing at a CAGR of 10% during the forecast period. The report offers an up-to-date analysis regarding the current...

at 17:20
The report on the global surgical gown market provides qualitative and quantitative analysis for the period from 2016 to 2024. Read the full report: https://www.reportlinker.com/p05751696/?utm_source=PRN The report predicts the global surgical gown...

at 17:10
The report on the global sinus dilation devices market provides qualitative and quantitative analysis for the period from 2016 to 2024. Read the full report: https://www.reportlinker.com/p05751705/?utm_source=PRN The report predicts the global sinus...

at 17:05
The report on the global self-injections market provides qualitative and quantitative analysis for the period from 2016 to 2024. Read the full report: https://www.reportlinker.com/p05751706/?utm_source=PRN The report predicts the global...

at 17:00
Global Regenerative Medicine Market 2020-2024 The analyst has been monitoring the global regenerative medicine market and it is poised to grow by USD 9.55 bn during 2020-2024, progressing at a CAGR of 20% during the forecast period. Our reports on...

at 16:30
PTC Therapeutics, Inc. today announced that the Company will host a webcast conference call to report its fourth quarter and year-end 2019 financial results and provide an update on the company's business and outlook on Monday, March 2, 2020 at 4:30...

News published on 30 april 2019 at 11:00 and distributed by: